Propensity for biofilm formation by clinical isolates from urinary tract infections: developing a multifactorial predictive model to improve the antibiotherapy by Alves, Maria José et al.
	   1	  
Propensity for biofilm formation by clinical isolates from urinary tract infections: 
developing a multifactorial predictive model to improve the antibiotherapy 
 
MARIA JOSÉ ALVES1,2,3,4, JOÃO C.M. BARREIRA3,5, INÊS CARVALHO4, LUIS 
TRINTA4, LILIANA PERREIRA4, ISABEL C.F.R. FERREIRA3,*, MANUELA 
PINTADO1,*  
 
1CBQF-Escola Superior de Biotecnologia, Universidade Católica Portuguesa Porto, 
Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. 
2Centro Hospitalar de Trás-os-Montes e Alto Douro- Unidade de Chaves, Av. Dr. 
Francisco Sá Carneiro, 5400-249 Chaves, Portugal.  
3Centro de Investigação de Montanha (CIMO), ESA, Instituto Politécnico de Bragança, 
Campus de Santa Apolónia, Apartado 1172, 5301-855 Bragança, Portugal. 
4Escola Superior de Saúde, Instituto Politécnico de Bragança, Av. D. Afonso V, 5300-
121 Bragança, Portugal. 
5REQUIMTE/Departamento de Ciências Químicas, Faculdade de Farmácia, 
Universidade do Porto, Rua Jorge Viterbo Ferreira n.º 228, 4050-313 Porto, Portugal. 
 
 
 
* Authors to whom correspondence should be addressed (e-mail: iferreira@ipb.pt, 
telephone +351-273-303219, fax +351-273-325405; e-mail: mpintado@porto.ucp.pt, 
telephone +351-22-5580097, fax +351-22-5090351).  
	   2	  
Abstract  
A group of biofilm producing bacteria isolated from patients with urinary tract 
infections was evaluated, identifying the main factors contributing to biofilm formation. 
Among the 156 isolates, 58 (37.2%) were biofilm producers. The bacterial species (p < 
0.001), together with patient’s genre (p = 0.022), were the factors with highest influence 
for biofilm production. There was also a strong correlation among catheterization and 
biofilm formation, despite being less significant (p = 0.070) than the former. In fact, 
some of the isolated bacteria were biofilm producer in all cases. Regarding resistance 
profile among bacterial isolates, the β-lactamic antibiotics presented the highest 
cases/percentages: ampicillin (32/55.2%), cephalothin (30/ 51.7%), 
amoxicillin/clavulanic acid (22/37.9%), although the carbapenemic group still represent 
a good therapeutic option (2/3.4%). Quinolones (nucleic acid synthesis inhibitors) also 
showed high resistance percentages. Furthermore, biofilm production clearly increases 
bacterial resistance. Actually, almost half of biofilm producing bacteria showed 
resistance against at least three different groups of antibiotics species. Bacterial 
resistance is often associated with catheterization. Accordingly, intrinsic (age and 
gender) and extrinsic (hospital unit, bacterial isolate and catheterization) were used to 
build a predictive model, by evaluating the contribution of each factor to biofilm 
production. In this way, it is possible to anticipate biofilm occurrence immediately after 
bacterial identification, allowing selecting a more effective antibiotic (among the 
susceptibility options suggested by the antibiogram) against biofilm producing bacteria. 
This approach reduces the putative bacterial resistance during the treatment, and the 
consequent  need to adjust antibiotherapy.  
Keywords: urinary tract infection; catheterization; biofilm; antibiotherapy; predictive 
model. 
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1. Introduction 
Implantable medical devices help enhancing therapeutic results, saving human lives and 
improving life quality of patients. However, these devices can be readily colonized by 
bacteria and fungi, since the presence of a foreign body will reduce the number of 
microorganisms necessary to produce an infection (Guggenbichler et al., 2011). Nearly 
50% of catheterized patients acquired infections after a short period of time (less than 7 
days) depending on the type and location of device. In addition, patients catheterized for 
long periods (28 days) have a 100% chance of developing infections (Dohnt et al., 
2011). 
Infections suffered during medical care are the fourth leading disease cause in 
industrialized countries, mostly due to the increase of evasive techniques such as 
catheters insertion and prostheses implantation, among others. According to a recent 
study, about 10% of the European population is hospitalized each year, among which 
5% acquire at least one nosocomial infection. A mortality rate of 10% is also estimated 
as being due to hospital infections (Guggenbichler et al., 2011). The Portuguese 
situation is even more alarming. According to the latest report of the Program for 
Infections and Antimicrobials Prevention and Control, 70% of the bacterial associated 
to nosocomial infections respond only to a single antibiotic (PPCIRA, 2013).   
In a report published by the National Nosocomial Infection Surveillance System, 
urinary tract infections are indicated as being among the most common causes of 
nosocomial infections, reporting that 97% of the cases were associated with urinary 
catheters (National System of Surveillance of Nosocomial Infection, 2002). Several 
biofilm producing agents (including bacteria, fungi and protozoa) have been related 
with these infections, and is known that biofilm presence is one of promoting factors, 
	   4	  
assuming that 60% of infection processes derive from biofilm presence (Ponnusamy et 
al., 2012; Tamilvanan et al., 2008).   
A consortium of microorganisms involving different groups might be found in the same 
biofilm, separated by interstitial spaces filled with surrounding fluid. The biofilm 
contains also water channels allowing the transport of essential nutrients and oxygen, 
contributing to the development of inner cells. The time required to form this biofilm on 
the device depends on the microbial consortium and the type of material, but in average 
a thick biofilm can be formed within 24 hours on the entire surface of polymeric devices 
(Tenke et al., 2012). Once the biofilm is formed, this will protect the pathogenic 
bacteria from action of antimicrobial agents and from the attack of immune response of 
the host (Guiton et al., 2010; Shoshani et al., 2011). This process can lead to chronic or 
recurrent infections hard to treat. If such urinary infections are not treated, there is the 
possibility of causing acute pyelonephritis, bacteremia, chronic bacterial prostatitis, 
bacterial vaginosis, chronic renal infection, bladder cancer and, in some cases, death 
(Guggenbichler et al., 2011; Guiton et al., 2010; Tenke et al., 2012). 
The biofilm structure and the physiological characteristics of its producing 
microorganisms allow an intrinsic resistance to antimicrobial agents. The resistance 
mechanisms are usually based on the delayed penetration of the antimicrobial agent, 
changes in the microbial growth rate or other physiological alterations related to the 
biofilm development (Donlan & Costerton, 2002). Due to the high mortality rates and 
expensive costs for health care, it is urgent to establish strategies to prevent and 
eradicate the development of biofilms on urinary tract catheters (Dohnt et al., 2011).  
Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus mirabilis, 
MRSA (methicillin-resistant Staphylococcus aureus) and Enterococcus spp. are the 
bacteria involved in urinary infections with greater biofilm production rates (Stahlhut et 
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al., 2012; Wasfi et al., 2012; Foxman et al., 2012; Al-Mathkhury et al., 2011; Bonkat et 
al., 2013). Furthermore, there’s the additional problem of the increased antibiotic 
resistance acquired by bacteria such as Staphylococcus aureus, Enterococcus species 
and different Gram negative bacilli (Guggenbichler et al., 2011). 
Despite some available studies on biofilms production in nosocomial infections 
(Singhai et al., 2012; Niveditha et al., 2012), the association with variables such as age, 
gender, hospital unit, bacteria, or catheterization, is not clear. Accordingly, the aims of 
this study were to: i) evaluate the capacity of bacteria isolated from patients with urinary 
tract infections to produce biofilms; ii) to evaluate the association of different variables 
(age, gender, hospital unit, bacteria, catheterization) with biofilm formation; and iii) to 
develop a model in order to understand the contribution of the studied variables as 
predictors of biofilm onset, allowing a more effective selection of the required antibiotic 
treatment.  
 
2. Materials and Methods 
 
2.1. Bacterial isolates 
A retrospective study was conducted during 5 months (February to June, 2013). During 
this period, 1370 urine specimens from patients with presumed urinary infection (with 
or without catheter) that were attended in the Clinical Pathology unit of Centro 
Hospitalar de Trás-os-Montes e Alto Douro (CHTMAD) were collected and the urine 
was inoculated onto Cystine Lactose Electrolyte Deficient (CLED) (Biomerieux; Marcy 
l´ Etoile, France) medium with calibrated loops to determine the Colony Forming Units 
(CFU). From positive samples (enumeration > 1x105 CFU/ml) the microorganisms were 
isolated for further characterization. From all positive samples, 156 bacterial isolates 
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were obtained. This study, duly approved by the Ethics Committee, was conducted in 
the CHTMAD, which is a public institution with 182 beds located in Chaves, North of 
Portugal.  
 
2.2. Isolates identification and antimicrobial susceptibility testing  
Microorganism’s identification and susceptibility tests were performed using 
MicroScan panels (MicroScan®; Siemens Medical Solutions Diagnostics, West 
Sacramento, CA) by microdilution plate method. The interpretation criteria were based 
on Interpretive Breakpoints as indicated in Clinical and Laboratory Standards Institute 
(CLSI) Document M100-S18 (Performance Standards for Antimicrobial Susceptibility 
Testing, 2008) and the report of the Committee of L'Antibiogramme de la Société 
Française de Microbiologie (CA-SFM) (Comité de L’Antibibiogramme De La Société 
Française de Microbiologie, 2008).  
 
2.3. Detection of biofilm formation 
The detection of biofilms was done by the tube adherence method. The investigation of 
the biofilm production was performed on the basis of the adherence of the biofilms to 
borosilicate test tubes following a previous methodology (Christensen et al., 1985) with 
minor changes. Each pure isolate was inoculated (0,5 McFarland) in borosilicate test 
tubes with 10 ml of Muller Hinton broth and incubated under aerobic conditions at 37 
°C, during 24 h (Tielen et al., 2011; Hassan et al., 2011). Then, the supernatants were 
discarded and the tubes were stained with 2 ml of violet crystal Sigma-Aldrich (Spruce 
Street; St. Louis, USA) for 5 min, washed with distilled water 3 times and dried (Al-
Mathkhury et al., 2011; Hassan et al., 2011). A positive result was defined as the 
presence of a layer on the stained material which adhered to the inner wall of the tubes. 
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The exclusive observation of a stained ring at the liquid-air interface was considered as 
negative. This method does not require high technological preparation, it is not 
expensive and it allows a suitable effectiveness level of biofilm screening, especially for 
thick biofilms, which were the main concern in this work. In fact, this methodology was 
previously reported as allowing the same results when compared to scanning electron 
microscopy (Singhai et al., 2012; Christensen et al., 1982).   
 
2.4. Predictive model 
Predictive models might be built based on regression techniques, clustering, decision 
trees or neural networks. In either case, the predictive model file might be used to 
generate predictive scores in other datasets. In the scoring process, data is transformed 
in a way that the model is expressed internally as a set of numeric transformations to be 
applied to a defined set of variables (the predictors specified in the model) in order to 
predict results from different datasets containing the same variables. The propensity to 
produce biofilm was assigned using different characteristics related with patients and 
infection: gender, age, bacterial isolate, clinical service, catheter use. Biofilm 
production was used in the response field, considering its presence as a positive 
response value. Hence, a binary logistic regression model was obtained, in which the 
target predictive score had only two possible outcomes (biofilm presence or absence). 
The model was built using a dataset (156 patients) for which the outcome of interest 
(biofilm formation) was known. The model was then tested with a different dataset to 
validate its usefulness in predicting biofilm formation.  
 
3. Results and Discussion 
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Biofilm development on urinary catheters is a problem often underestimated. However, 
this factor highly promotes the urinary tract infection, which leads to high mortality 
rates, prolonged treatments and causes high costs in health care services (Dohnt et al., 
2011). The most serious urinary infections are caused by E. coli, which is responsible 
for nearly 90% of the infections acquired in the community and 50% of urinary 
nosocomial infections that have also been associated with biofilms (Soto et al., 2007; 
Donlan & Costerton, 2002). Ages above 65 years and belonging to the female genus 
were previously reported as risk factors for bacteriuria (Guggenbichler et al., 2011; 
Niveditha et al., 2012). Also, the use of indwelling devices (more than 14 days), such as 
catheters, highly increases the risk of getting a urinary tract infection (Niveditha et al., 
2012). 
In our study, during covered period, from the 1370 requests of urine bacteriological 
analysis, 156 patients exhibited urinary tract infection. The mean age of patients was 64 
years (6 months - 97 years), they were predominantly female (71.2%) and were 
submitted to bladder catheters in 23.1% (36 patients) of the cases; E. coli was the 
microorganism isolated in most cases (100; 64.1%) corroborating the results from 
previous studies (Eshwarappa et al., 2011; Ronald, 2002; Niveditha et al., 2012), 
followed by K. pneumoniae (33; 21.2%) and P. mirabilis (9; 5.8%). Among the 156 
isolates, 58 (37.2%) were biofilm producers. In similar studies (Niveditha et al., 2012; 
Reid et al., 1992; Ponnusamy et al., 2012), the biofilm producing isolates were detected 
in higher percentages (>60%); this difference might result from the fact that these 
studies were performed only in patients with bladder catheters, while in present study 
we included all the positive cases, among which only 36 patients (23.1%) were 
submitted to bladder catheters. Soto et al. (2007) performed a similar study to the one 
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described herein, in which the biofilm production was detected in 46% of the cases, a 
value also closer to the one obtained in the present work.  
The average age for patients with biofilms was slightly higher (66.8 years, 6 months to 
97 years); however, there was no statistically significant correlation (p = 0.260) among 
age and biofilm production variables. The fact of being a woman seemed to have a 
significant influence for biofilm production (p = 0.022), since 35 (60,3%)	  of the 58 
patients with biofilm development, were isolated from woman, which is actually in 
agreement with previous results (Niveditha et al., 2012). On the other hand, only 18 
(31%) of the 58 patients were catheterized; thereby, the statistical correlation among 
both variables lay below 95% (p = 0.07). Despite lacking high statistical significance, 
the presence of a urinary catheter seemed to be a risk factor for biofilm production, as it 
was previously pointed out (Niveditha et al., 2012; Tenke et al., 2006; Reid et al., 
1992). Some complex features typical from biofilm producing bacteria promote 
antibiotic resistance, leading to infection processes related to the applied catheters 
(Singhai et al., 2012). Mechanisms responsible for resistance may be the following: (i) 
delayed penetration of the antimicrobial agent through the biofilm matrix, (ii) altered 
growth rate of biofilm organisms, and (iii) other physiological changes due to the 
biofilm mode of growth (Donlan & Costerton, 2002). 
The medical specialty with the highest percentage of biofilm producing bacterial 
isolates was Emergency (31; 53.5%), followed by Nephrology Appointment (13; 
22.4%), despite the reduced statistical correlation between this two variables (p = 
0.744). 
On the first stage, urinary catheters may be colonized by a single pathogen such as S. 
epidermidis, E. coli, E. faecalis, or P. mirabilis. However, over time, microbial diversity 
might increase, comprising additional species like Providencia stuartii, K. pneumoniae 
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(Stickler, 1996), Morganella morganii, Acinetobacter calcoaceticus (Stickler et al., 
1993a) or Enterobacter aerogenes (Stickler et al., 1993b). Despite E. coli being 
detected as the most common biofilm producing bacteria (Table 1), species like P. 
mirabilis, M. morganii, Citrobacter freundii, K. oxytoca and A. baumanni, were always 
biofilm producers, confirming the previous information. It is possible that some 
microorganisms (in particular Proteus) change pH values by producing urease, which 
hydrolyzes urea to ammonia (Tunney et al., 1999). Ammonia increases pH value, 
promoting the precipitation of minerals, which in turn are deposited on catheters 
causing mineral inlays and stimulating biofilms production. Urease producing 
microorganisms in urinary catheters are usually P. mirabilis, K. pneumoniae, M. 
morganii, P. aeruginosa and P. vulgaris (Tunney et al., 1999; Stickler et al., 1993a); 
this specification also meets our results, according to the detected statistical significance 
between bacterial species and biofilm production (p <0.001). 
Regarding resistance profile among bacterial isolates (Table 2), β-lactam antibiotics 
presented the highest percentages: ampicillin (36; 62.1%), cephalothin (33; 56.9%), 
amoxicillin/clavulanic acid (22; 37.9%), although the carbapenemic group still represent 
a good therapeutic option (2; 3.4%). Quinolones (nucleic acid synthesis inhibitors) also 
showed high resistance percentages (nalidixic acid: 30, 51.7%; norfloxacin: 25, 43.1%; 
ciprofloxacin: 21, 36.2%). 
These resistances might be related with the above described mechanisms, as in the case 
of biofilm producing P. aeruginosa, for which ciprofloxacin had a delay in penetration 
time (21 minutes compared with the usually required 40 seconds) (Suci et al., 1994). 
After carbapenemics, gentamicin and tobramycin (both protein synthesis inhibitors) 
were the antibiotics with lowest resistance percentages (17.2 and 15.5%, respectively); 
nonetheless, the detected resistance is matter of concern, since bacteria might be up to 
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15 times more resistant to tobramycin when the biofilm formation occurs (Hoyle et al., 
1992). In fact, the so called persistent cells are not resistant to antibiotics per si, 
acquiring resistance only when the biofilm is formed (Lynch & Robertson, 2008). 
Fosfomycin also appears to be an alternative therapy for these cases, despite the 
observed resistance (22.4%). Quinolones group was the second one with the highest 
percentages of resistance (>70%), in line with the results obtained in a similar study 
(Niveditha et al., 2012). 
The 58 producing biofilm isolates were multi-resistant in 44.8% of the cases, compared 
with only 28.6% among the 98 non-biofilm producers; this strongly indicates that 
biofilm production increases the resistance profile of the microorganisms. Almost half 
of biofilm producers are simultaneously resistant to at least 3 different groups of 
antibiotics. Co-trimoxazole (44.9%) and ciprofloxacin (41.8%) (Table 2) showed high 
resistance percentages, even in non-producing biofilm isolates, probably due to 
excessive and inappropriate use of these antibiotics in particular in urinary tract 
infections. 
Overall, microbial biofilms are a clinical reality closely linked to a variety of persistent 
infections that respond poorly to conventional antibiotherapy. Accordingly, biofilms 
greatly complicate the clinical use of antimicrobials. The pharmacokinetic and 
pharmacodynamic studies for antibiotics applied to infections are conducted using 
parameters such as minimum inhibitory concentration (MIC) for bacteria isolated from 
clinical samples, which behave as planktonic bacteria. Two crucial data are still missing 
in order to establish the best treatment for bacteria in biofilm: it is known that the MIC 
of these bacteria are always higher than in planktonic, however it is not known to what 
extent; on the other hand, the presence of more than one bacterial species in the same 
biofilm is an aggravation factor. 
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These limitations led us to consider the need of developing a predictive model to 
anticipate the probability of biofilm occurrence according to different related variables. 
The file used to obtain a predictive model regarding the targeted outcome (biofilm 
formation) included variables inherent (age and gender) to the 156 patients with 
bacterial isolates and to the clinical condition (bacterial isolate, catheterization, clinical 
unit), all used as predictor variables, and, of course, information regarding the 
development of biofilm during antibiotic treatment (a value of 1 indicates “biofilm 
positive”, while a value of 0 indicates “biofilm negative”), used in the response field. 
The obtained model was provided as supplementary material, since it would be 
impracticable to be presented in results and discussion section due to its complexity. 
The model was validated by using the default training sample partition size of 50% and 
the default seed value of 2000000. The overall model quality was also verified (Figure 
1). The obtained value (0.67) indicates a good ability to predict the targeted outcome, 
but this result should be interpreted carefully since it only reflects a general measure of 
overall model quality. In fact, the model quality might even be considered “good” if the 
correct prediction rate for positive responses does not meet the specified minimum 
probability. To overcome this limitation we should examine the obtained classification 
table (Table 3) to verify correct prediction rates. The classification table is split into a 
training sample and a testing sample. The training sample was used to build the model, 
which was then applied to the testing sample to evaluate the model effectiveness. The 
selected minimum biofilm formation probability was 0.9 (or 90%). The correct 
classification rate for positive biofilm is 100.00% in the training sample and 90.91% in 
the testing sample. Since the testing sample response rate is higher than 90%, the 
obtained model should be able to predict if a patient is prone to develop biofilm with at 
least 90% of probability. 
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Nevertheless, it should be clarified that its application range is limited to the population 
to which patients belong. To achieve a transnational, or even transregional, dimension, 
the dataset used to build the predictive model should include patients from different 
countries or regions.  
To evaluate the predictive ability, a dataset (Table 4) from patients whom have not been 
used to obtain the predictive model was tested. The dataset included the same variables 
as those used as predictors (age, gender, bacterial isolate, catheterization, clinical 
service). The results were classified using the scoring wizard (SPSS) that allows 
different scoring functions (i.e., the types of “scores” available for the selected model). 
For the binary logistic model used in this study, the available functions are predicted 
value, probability of the predicted value, probability of a selected value, and confidence. 
Due to its simplicity, we opted for the predicted value function, which gives straightly a 
“yes” (value 1) or “no” (value 0) as answer. After applying the model to the testing 
dataset, it was verified that all patients were correctly classified as producing (positive) 
or not (negative) biofilm in agreement with the observed in hospital environment. 
Hence, and despite the limitation of the number of cases (which ideally would be 
greater) used to obtain the predictive model, this result might have the potential to 
anticipate the formation of biofilm among the studied population, allowing to define the 
most suitable and effective antibiotic therapy, offering health advantages to the patients 
and financial benefits to the health care institutions. 
Decreasing biofilm formation would be a different approach, but it seems rather 
difficult. More knowledge is needed regarding the molecular mechanisms that lead to 
the production of biofilms; furthermore, genetic regulation and expression of genomic 
factors might allow preventing or decreasing biofilm formation, but this subject is still 
at basic research stage.  
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Thus, the statistical approach might be useful, since after identifying the bacteria and 
considering certain characteristics of the patient, the biofilm production can be predicted 
immediately. This might help preventing multibacterial urinary infection especially in 
patients with bladder catheters and choosing more effective antibiotic therapies; i.e., 
among the options given by the antibiogram, the clinician may select an antibiotic from 
a most advanced generation within the same group, in the case of biofilm-producing 
strain, thus reducing the possibility of appearance of new resistances. In fact, when the 
biofilm is developed, the effectiveness of the selected antibiotic is lower and it is often 
required to readjust the antibiotherapy. Accordingly, anticipating biofilm formation in 
those cases where information is not available during identification of bacterial isolates, 
might allow choosing a more suitable antibiotic in the beginning of the treatment 
instead of having the need to change antibiotics in a later stage.	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Table 1. Screening results for biofilm formation among the 156 urinary isolates.  
Bacterial isolate Biofilm positive (%) MDR* in biofilm positive isolates Biofilm non-producers (%) Total 
Acinectobacter baumannii 2 (100%) 2 (100%) 0 2 
Citrobacter freundii 3 (100%) 1 (33.3%) 0 3 
Enterobacter aerogenes 2 (50%) 2 (100%) 2 (50%) 4 
Escherichia coli  22 (22%) 6 (28.6%) 78 (78%) 100 
Klebsiella oxytoca 2 (100%) 1 (50%) 0 2 
Klebsiella pneumoniae  10 (37.0%) 5 (100%) 17 (63.0%) 27 
Morganella morganii 3 (100%) 3 (100%) 0 3 
Proteus mirabilis 9 (100%) 7 (77.8%) 0 9 
Pseudomonas aeruginosa 5 (83.3%) 1 (20%) 1 (16.7%) 6 
Total 58 26 98 156 
*A multidrug-resistant (MDR) organism was defined if resistant to all tested antimicrobials in 3 or more classes of antimicrobial agents 
(penicillins/cephalosporins, carbapenems, aminoglycosides and quinolones) not including tetracyclines or colistin (Sanchez et al., 2013). 
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Table 2. Antibiotic resistance profiles for biofilm positive and negative isolates. 
Antibiotics 
Resistance 
Biofilm positive 
(n=58) 
Biofilm negative 
(n=98) 
Resistance of all isolates 
(n=156) 
Amoxicillin/clavulanic acid 22 (37.9%) 25 (25.5%) 47 (30.1%) 
Ampicillin 36 (62.1%) 67 (68.4%) 103 (66.0%) 
Cephalothin  33 (56.9%) 55 (56.1%) 88 (56.4%) 
Cefazolin  26 (44.8%) 33 (33.7%) 59 (37.8%) 
Cefoxitin 23 (39.7%) 25 (25.5%) 48 (30.8%) 
Cefuroxime 24 (41.4%) 25 (25.5%) 49 (31.4%) 
Cefotaxime 18 (31.0%) 21 (21.4%) 39 (25.0%) 
Ceftazidime 16 (27.6%) 21 (21.4%) 37 (23.7%) 
Cefepime 13 (22.4%) 21 (21.4%) 34 (21.8%) 
Fosfomycin 14 (24.1%) 7 (7.1%) 21 (13.5%) 
Nalidixic acid 30 (51.7%) 50 (51.0%) 80 (51.3%) 
Ciprofloxacin 21 (36.2%) 41 (41.8%) 62 (39.7%) 
Norfloxacin 25 (43.1%) 43 (43.9%) 63 (40.4%) 
Nitrofurantoin 16 (27.6%) 16 (16.3%) 32 (20.5%) 
Gentamicin 12 (20.7%) 17 (17.3%) 29 (18.6%) 
Tobramycin 12 (20.7%) 18 (18.5%) 30 (19.2%) 
Co-trimoxazole 20 (34.5%) 44 (44.9%) 64 (41.0%) 
Piperacillin/tazobactam 7 (12.1%) 10 (10.2%) 17 (10.9%) 
Imipenem 2 (3.4%) 1 (1.0%) 3 (1.9%) 
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Table 3. Classification table with scores obtained for training and testing samples.  
Observed 
Predicted* 
Training sample Testing sample 
Response recoded  
(1=positive, 2= negative) 
Percentage  
correct 
Response recoded  
(1=positive, 2= negative) 
Percentage 
correct 
Positive Negative Positive Negative 
Response recoded  
(1=positive, 2= negative) 
Positive 9 16 36.00 10 18 35.71 
Negative 0 45 100.00 1 52 98.11 
Overall percentage 100.00 26.23 77.14 90.91 25.71 76.54 
*For the cases predicted to have a positive response, the correct classification rate for actual positive responses is 100.00% for training sample and 90.91% for 
testing sample. This is greater than the specified minimum probability of 0.90 or 90.00%. This suggests that the obtained model could be used to identify a set 
of patients that would have at least 90% chances of bacterial biofilm developing. 
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Table 4. Dataset used to evaluate the obtained predictive model. 
Age group Gender Bacterial isolate Catheterization Clinical service Predicted value 
80 to 89 years Male Escherichia coli Yes Nephrology appointment 1 
70 to 79 years Male Escherichia coli No Internment medicine 0 
80 to 89 years Female Escherichia coli No Emergency 0 
40 to 49 years Female Escherichia coli No External appointment 0 
60 to 69 years Female Klebsiella pneumoniae ESBL No Internment medicine 0 
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Figure 1. Overall quality for the obtained predictive model. A good model has a value 
above 0.5; when this value is lower it indicates that the model is no better than random 
prediction.	  
	  
	  
 
 
 
 
